River Wealth Advisors Boosts Stake in Eli Lilly

Investment firm increases holdings in pharmaceutical giant by 10.9% in Q3

Mar. 3, 2026 at 12:31am

Got story updates? Submit your updates here. ›

River Wealth Advisors LLC, an investment management firm, has increased its stake in Eli Lilly and Company (NYSE: LLY) by 10.9% during the third quarter of 2026, according to a recent 13F filing with the SEC. The firm now owns 12,316 shares of the pharmaceutical company's stock, valued at $9,397,000 as of the most recent filing.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, known for developing innovative drugs and therapies. The increase in River Wealth Advisors' stake suggests the firm sees continued growth potential in Lilly's business and stock performance.

The details

According to the 13F filing, River Wealth Advisors acquired an additional 1,213 shares of Eli Lilly during the third quarter, bringing its total position to 12,316 shares. Eli Lilly makes up 1.1% of River Wealth Advisors' overall investment portfolio, making it the firm's 24th largest holding.

  • River Wealth Advisors filed the 13F report disclosing the increased Eli Lilly stake on March 1, 2026.
  • The additional 1,213 Eli Lilly shares were acquired by River Wealth Advisors during the third quarter of 2026.

The players

River Wealth Advisors LLC

An investment management firm that oversees a portfolio of stocks, bonds, and other assets for its clients.

Eli Lilly and Company

A global pharmaceutical company that researches, develops, manufactures, and commercializes a broad range of medicines and therapies.

Got photos? Submit your photos here. ›

The takeaway

River Wealth Advisors' increased stake in Eli Lilly suggests the firm sees continued growth potential in the pharmaceutical company's business and stock performance. As one of the world's largest drug makers, Eli Lilly's performance is closely watched by investors and analysts.